Amarin Reports (REDUCE-IT) Trial Results of Vascepa/Vazkepa (icosapent ethyl) for Cardiovascular Diseases
- The (REDUCE-IT) trial to evaluate the effect of Vascepa vs PBO in 8179 adult patients with CV disease with LDL-C at ~400 clinical sites in 11 countries
- The results showed a reduction in first and total CV events in combined current & former smokers (23% & 29%) in the post hoc exploratory analysis, a reduction in the incidence of CV events in current smokers (23.8%) & former smokers (23.0%) compared with never smokers (25.7%) in the PBO group. The results were presented at ESC 2022 & published in EHJ cardiovascular pharmacotherapy
- In Jan 2020, Vascepa has been launched in the US as the first approved therapy for high-risk patients with persistent CV risk after statin therapy
Ref: Globenewswire | Image: Amarin
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.